ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
21.30
-0.07 (-0.33%)
At close: Nov 21, 2024, 4:00 PM
21.31
+0.01 (0.05%)
After-hours: Nov 21, 2024, 5:12 PM EST
ADMA Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 21.25, with a low estimate of 14 and a high estimate of 26. The average target predicts a decrease of -0.23% from the current stock price of 21.30.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +22.07% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +17.37% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -15.49% | Oct 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $20 | Buy | Reiterates | $20 | -6.10% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $18 | Strong Buy | Maintains | $10 → $18 | -15.49% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
414.21M
from 258.22M
Increased by 60.41%
Revenue Next Year
468.41M
from 414.21M
Increased by 13.09%
EPS This Year
0.49
from -0.13
EPS Next Year
0.67
from 0.49
Increased by 36.93%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 430.8M | 490.6M | 562.5M | ||
| Avg | 414.2M | 468.4M | 523.0M | ||
| Low | 393.9M | 440.4M | 487.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 66.8% | 18.4% | 20.1% | ||
| Avg | 60.4% | 13.1% | 11.7% | ||
| Low | 52.5% | 6.3% | 4.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.51 | 0.77 | 0.84 | ||
| Avg | 0.49 | 0.67 | 0.75 | ||
| Low | 0.45 | 0.58 | 0.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 55.9% | 24.8% | ||
| Avg | - | 36.9% | 11.7% | ||
| Low | - | 17.6% | 1.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.